Panobinostat with bortezomib and dexamethasone in relapsed or relapsed-and-refractory multiple myeloma
- Conditions
- Multiple MyelomaMedDRA version: 21.0Level: LLTClassification code 10028228Term: Multiple myelomaSystem Organ Class: 100000004864Therapeutic area: Diseases [C] - Cancer [C04]
- Registration Number
- EUCTR2015-001564-19-NL
- Lead Sponsor
- Secura Bio, Inc.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- 240
- Multiple Myeloma as per IMWG 2014 definition
- Requiring treatment for relapsed or relapsed/refractory disease
- Measurable disease based on central protein assessment
- 1 to 4 prior lines of therapy
- Prior IMiD exposure
- Acceptable lab values prior to starting study treatment
Other protocol-defined inclusion criteria may apply.
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 111
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 137
- Primary refractory myeloma
- Refractory to bortezomib i.e. patients who progressed while receiving salvage
therapy with BTZ, or patients who progressed within 60 days of their most recent BTZ containing treatment.
- Concomitant anti-cancer therapy (other than BTZ/Dex and bisphosphonates)
- Prior treatment with DAC inhibitors
- Clinically significant, uncontrolled heart disease and/or recent cardiac event (within 6 month prior to screening)
- Unresolved diarrhea = CTCAE grade 2 or presence of medical condition associated with chronic diarrhea (such as irritable bowel syndrome, inflammatory bowel disease)
Other protocol-defined exclusion criteria may apply.
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method